SCHEMBL132476

SCHEMBL132476

COC(=O)CCCCCN(C)C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.49
CCR6 P51684 1/20 0.48
PAX8 Q06710 1/20 0.48
LTA4H P09960 1/20 0.46
LMNA P02545 5/20 0.45
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
CYP3A4 P08684 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
BCHE P06276 2/20 0.45
ACHE P22303 2/20 0.45
F13A1 P00488 1/20 0.44
TGM2 P21980 1/20 0.44
TGM1 P22735 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
MAPK1 P28482 2/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9232890 1.00 ABCB1 (0.49) ABCB1CCR6PAX8LTA4HLMNA
SCHEMBL21235941 0.99 ABCB1 (0.50) ABCB1CCR6PAX8LTA4HLMNA
SCHEMBL10478127 0.89 ABCB1 (0.53) ABCB1CCR6PAX8LTA4HLMNA
SCHEMBL392019 0.88 HTT (0.50) CCR6PAX8LMNAALDH1A1MAPT
SCHEMBL28002371 0.88 HTT (0.50) CCR6PAX8LMNAALDH1A1MAPT
SCHEMBL389007 0.86 HTT (0.51) CCR6PAX8LTA4HALDH1A1KMT2A
SCHEMBL9684805 0.85 ALDH1A1 (0.47) ABCB1CCR6PAX8LMNAALDH1A1
SCHEMBL392903 0.85 ALDH1A1 (0.47) ABCB1CCR6PAX8LMNAALDH1A1
SCHEMBL16306384 0.85 ALDH1A1 (0.46) ABCB1CCR6PAX8LTA4HALDH1A1
SCHEMBL21235957 0.85 CCR6 (0.48) ABCB1CCR6PAX8LTA4HLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979331-B1 TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-07 EP disclosed
US-8076364-B2 Trisubstituted amine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-12-13 US disclosed
US-20110092506-A1 TRISUBSTITUTED AMINE COMPOUND NAKAMURA YOSHINORI 2011-04-21 US disclosed
US-7906517-B2 Trisubstituted amine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-03-15 US disclosed
US-20090029994-A1 Trisubstituted amine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-29 US disclosed
US-20090023729-A1 Trisubstituted amine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-22 US disclosed
EP-1979331-A1 TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP Mitsubishi Tanabe Pharma Corporation (JP) 2008-10-15 EP disclosed
EP-1979341-A1 TRISUBSTITUTED AMINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2008-10-15 EP disclosed
WO-2007088996-A1 TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed
WO-2007088999-A1 TRISUBSTITUTED AMINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092506-A1 TRISUBSTITUTED AMINE COMPOUND CETP, MTTP, APOB ABCB1 170/4885CCR6 3201/4885PAX8 4871/4885
US-20090029994-A1 Trisubstituted amine compound CETP, MTTP, APOB ABCB1 170/4885CCR6 3201/4885PAX8 4871/4885
US-20090023729-A1 Trisubstituted amine compound CETP, MTTP, APOB ABCB1 156/4885CCR6 2673/4885PAX8 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.